News Conference News ESC 2022 DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark L.A. McKeown August 30, 2022
News Conference News ESC 2022 First Cardio-Oncology Guidelines From ESC Cover ‘Tremendous’ Territory L.A. McKeown August 26, 2022
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2021 Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival Caitlin E. Cox September 01, 2021
News Conference News ESC 2020 More Than Half of Patients See a GP in the 2 Weeks Before OHCA Yael L. Maxwell August 28, 2020
News Conference News ESC 2019 Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories Yael L. Maxwell September 06, 2019
News Conference News ESC 2019 New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL Michael O'Riordan September 05, 2019
News Conference News ESC 2019 Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART Yael L. Maxwell September 04, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ESC 2018 Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61 Michael O'Riordan August 26, 2018
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017